Intercell — BrandWiki

Intercell

Overview

Intercell AG

type	Aktiengesellschaft
traded as	WBAG: ICLL OTCQX: INRLY
foundation	1998
location city	Vienna
location country	Austria
key people	Thomas Lingelbach (CEO), Michel Gréco (Chairman of the supervisory board)
industry	Biotechnology
fate	Merged with Vivalis SA
successor	Valneva SE
defunct	2013
products	Development of vaccines
revenue	€34.2 million (2010) ‡R1R‡
operating income	(€251.2 million) (2010) ‡R1R‡
net income	(€255.2 million) (2010) ‡R1R‡
assets	€225.2 million (end 2010) ‡R1R‡
equity	€121.1 million (end 2010) ‡R1R‡
num employees	410 (average, 2010) ‡R1R‡
homepage	http://www.intercell.com/

Intercell AG was a biotechnology company based in Vienna which focused on the development of modern prophylactic and therapeutic vaccines against infectious diseases. The company merged with Vivalis to form Valneva SE in 2012.[2] Intercell was formed in 1998 as a spin-off of the Research Institute of Molecular Pathology (IMP) in Vienna.[3] It employs 400 people in Austria, Scotland and the United States.

History

It was founded in 1998 and focused on the research, development, and commercialization of vaccines and other biological products. Intercell AG's products were used to prevent and treat a variety of infectious diseases, including hepatitis B, Japanese encephalitis, and pneumonia. In 2012, Intercell AG merged with Vivalis SE, a French biotech company, to form Valneva.[4]

It has been listed on the Vienna Stock Exchange

Intercell

History

External links

References